A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.

Overview of attention for article published in Clinical Cancer Research, February 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

blogs: 1 blog

twitter: 8 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 15 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 1 blog post.

An Efficacy

Physician's Weekly, 20 Jun 2022

For a phase Ib/II study, researchers looked at the safety and efficacy of ribociclib plus docetaxel (mCRPC) for metastatic…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.